Citation: Dw. Ollila et al., OVERVIEW OF MELANOMA VACCINES - ACTIVE SPECIFIC IMMUNOTHERAPY FOR MELANOMA PATIENTS, Seminars in surgical oncology, 14(4), 1998, pp. 328-336
Authors:
HOON DSB
OKAMOTO T
WANG HJ
ELASHOFF R
NIZZE AJ
FOSHAG LJ
GAMMON G
MORTON DL
Citation: Dsb. Hoon et al., IS THE SURVIVAL OF MELANOMA PATIENTS RECEIVING POLYVALENT MELANOMA CELL VACCINE LINKED TO THE HUMAN-LEUKOCYTE ANTIGEN PHENOTYPE OF PATIENTS, Journal of clinical oncology, 16(4), 1998, pp. 1430-1437
Authors:
MANDER T
HILL S
HUGHES A
RAWLINS P
CLARK C
GAMMON G
FOXWELL B
MOORE M
Citation: T. Mander et al., DIFFERENTIAL-EFFECTS ON TNF-ALPHA PRODUCTION BY PHARMACOLOGICAL AGENTS WITH VARYING MOLECULAR SITES OF ACTION, International journal of immunopharmacology, 19(8), 1997, pp. 451
Authors:
BROWN D
SADEGHI R
STEEL J
MOORE M
GAMMON G
Citation: D. Brown et al., DETECTION OF INTERLEUKIN-1 SIGNAL-TRANSDUCTION INHIBITORS - ACTION OFPROTEIN-KINASE INHIBITORS, International journal of immunopharmacology, 17(11), 1995, pp. 887-894
Authors:
GAMMON G
CHANDLER G
DEPLEDGE P
ELCOCK C
WRIGLEY S
MOORE J
CAMMAROTA G
SINIGAGLIA F
MOORE M
Citation: G. Gammon et al., A FUNGAL METABOLITE WHICH INHIBITS THE INTERACTION OF CD4 WITH MAJOR HISTOCOMPATIBILITY COMPLEX-ENCODED CLASS-II MOLECULES, European Journal of Immunology, 24(4), 1994, pp. 991-998
Authors:
CHANDLER G
ELCOCK C
DEPLEDGE P
WRIGLEY S
MOUS J
MALKOVSKY M
MOORE M
GAMMON G
Citation: G. Chandler et al., CD4-BINDING COMPOUNDS - AN ASSAY TO DETECT NEW CLASSES OF IMMUNOPHARMACOLOGICAL AGENTS, International journal of immunopharmacology, 15(3), 1993, pp. 361-369